Launched in collaboration with DeciBio in October 2022, the BroadOak BioTools Venture Fund provides early stage growth capital to promising young companies. With a world-class ecosystem of investors, strategics, and mentors, BroadOak BioTools Venture Fund offers pre-commercial companies tremendous value to accelerate their growth.
Managing Director, BioTools Venture Fund
Managing Director, BroadOak
Managing Director, BioTools Venture Fund
Principal, DeciBio
About DeciBio
DeciBio is a strategy consulting and market intelligence firm serving clients across the precision medicine ecosystem.
DeciBio’s specialized team of life science experts has a unique perspective on precision medicine. From early-stage research to commercialization and the patient journey, the DeciBio team understands how market developments impact the precision medicine ecosystem. They thrive in markets that require the unique combination of deep scientific understanding and business insights.
DeciBio's industry-leading strategic consulting combined with BroadOak's depth of experience and network makes BroadOak's BioTools Venture Fund a natural choice for early-stage companies in need of growth capital.
Austin Duke
Managing Director, BroadOak
BroadOak has invested in more than 70 outstanding companies. Get to know our portfolio companies.
Stay connected
Partner with BroadOak